[Presentation] Financial Results for the Fiscal Year Ended March 31, 2022 (Slides and Audio Recording)
[Presentation] Financial Results for the Fiscal Year Ended March 31, 2022 (Slides)
Notice concerning Application for Marketing Authorization of KD-370, Combination Vaccine for Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib
Notice concerning Submission of Clinical Trial Notifications for KD-414, Inactivated COVID-19 Vaccine
Meiji invests in PLIMES, a start-up developing a monitoring service for feeding and swallowing
Invest in Meiji
How we deliver long-term growth and shareholder returns.
What we're aiming for and how we'll get there.
You may also be interested in
The Meiji Group promotes innovation through a unique synergy between food and pharmaceutical expertise.
Meiji Group's drug development pipeline ranges from areas of core expertise through to follow-on biologics, generic anti-cancer drugs, and agrochemicals.
The Meiji Group believes in good health – not just for people, but for our society and planet too. Read about our sustainability management policies on this page.